Commercial Strategy
ELARA is committed to rapid preclinical development
and validation of its lead series. Our goal is to further enhance
the development of our lead series through a combination of partnering
with biotech-pharma and equity capital investment. Our early preclinical
lead series are available for partnering or out-licensing. An
essential prerequisite is that such potential partners and investors
share our sense of urgency and have a proven track record of progressing
discovery projects into development. They are expected to complement
ELARA’s capabilities and network.
investors
Elara was founded in July of 2006 with seed capital
from EMBL Ventures. The intellectual properties was licensed exclusively
to ELARA by EMBL- EM.
Contact ELARA:
Dr Joe Lewis, CEO
Elara Pharmaceuticals GmbH
Boxbergring 107
69126 Heidelberg
Germany
Email: j.lewis@elarapharma.com
Tel: +49 (0)6221 387 8935
Mobile: +49(0)160843 8979
Fax: +49 (0)6221 387 8971
Web: www.elarapharma.com |
Contact EMBL Ventures:
Edeltraut Günterberg
EMBL Ventures GmbH
Boxbergring 107
D-69126 Heidelberg
Germany
Email: guenterberg@embl-ventures.com
Tel: +49 (0)6221 389 3322
Fax: +49 (0)6221 389 3311
Web: www.embl-ventures.com
|